Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial. (abre nova janela)

CRASH-3 Trial Collaborators

Fonte‎: Lancet 2019;394(10210):1713-23.

Indexado‎: PubMed 31623894

DOI‎: 10.1016/S0140-6736(19)32233-0

https://www.ncbi.nlm.nih.gov/pubmed/31623894 (abre nova janela)

Alternatives to allogeneic platelet transfusion. (abre nova janela)

Desborough MJ, Smethurst PA, Estcourt LJ, Stanworth SJ.

Fonte‎: Br J Haematol 2016;175(3):381-92.

Indexado‎: PubMed 27650431

DOI‎: 10.1111/bjh.14338

https://www.ncbi.nlm.nih.gov/pubmed/27650431 (abre nova janela)

Tranexamic acid: less bleeding and less thrombosis? (abre nova janela)

Godier A, Roberts I, Hunt BJ.

Fonte‎: Crit Care 2012;16(3):135.

Indexado‎: PubMed 22748073

DOI‎: 10.1186/cc11374

https://www.ncbi.nlm.nih.gov/pubmed/22748073 (abre nova janela)

Tranexamic acid for reducing mortality in emergency and urgent surgery. (abre nova janela)

Perel P, Ker K, Morales Uribe CH, Roberts I

Fonte‎: Cochrane Database Syst Rev 2013;(1):CD010245.

Indexado‎: PubMed 23440847

DOI‎: 10.1002/14651858.CD010245.pub2

https://www.ncbi.nlm.nih.gov/pubmed/23440847 (abre nova janela)

The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. (abre nova janela)

Roberts I, Shakur H, Afolabi A, Brohi K, Coats T, Dewan Y, Gando S, Guyatt G, Hunt BJ, Morales C, Perel P, Prieto-Merino D, Woolley T; CRASH-2 collaborators.

Fonte‎: Lancet 2011;377(9771):1096-101, 1101.e1-2.

Indexado‎: PubMed 21439633

DOI‎: 10.1016/S0140-6736(11)60278-X

https://www.ncbi.nlm.nih.gov/pubmed/21439633 (abre nova janela)

Antifibrinolytic drugs for acute traumatic injury. (abre nova janela)

Roberts I, Shakur H, Ker K, Coats T; CRASH‐2 Trial collaborators.

Fonte‎: Cochrane Database Syst Rev 2011;(1):CD004896.

Indexado‎: PubMed 21249666

DOI‎: 10.1002/14651858.CD004896.pub3

https://www.ncbi.nlm.nih.gov/pubmed/21249666 (abre nova janela)

Use of tranexamic acid to reduce bleeding in burns surgery. (abre nova janela)

Tang YM, Chapman TW, Brooks P

Fonte‎: J Plast Reconstr Aesthet Surg 2012;65(5):684-6.

Indexado‎: PubMed 21983540

DOI‎: 10.1016/j.bjps.2011.09.028

https://www.ncbi.nlm.nih.gov/pubmed/21983540 (abre nova janela)

Tranexamic acid reduced blood transfusions in acute burn surgery: a retrospective case-controlled trial. (abre nova janela)

Tapking C, Hundeshagen G, Kirchner M, Fischer S, Kneser U, Bliesener B

Fonte‎: Burns. 2022;48(3):522-28.

Indexado‎: PubMed 35339324

DOI‎: 10.1016/j.burns.2022.03.002

https://pubmed.ncbi.nlm.nih.gov/35339324/ (abre nova janela)

Salvage use of activated recombinant factor VII in the management of refractory bleeding following cardiac surgery. (abre nova janela)

Barua A, Rao VP, Ramesh B, Barua B, El-Shafei H.

Fonte‎: J Blood Med 2011;2:131-4.

Indexado‎: PubMed 22287872

DOI‎: 10.2147/JBM.S21609

https://www.ncbi.nlm.nih.gov/pubmed/22287872 (abre nova janela)

The treatment of bleeding is to stop the bleeding! Treatment of trauma-related hemorrhage. (abre nova janela)

Boffard KD, Choong PI, Kluger Y, Riou B, Rizoli SB, Rossaint R, Warren B; NovoSeven Trauma Study Group.

Fonte‎: Transfusion 2009;49 Suppl 5:240S-7S.

Indexado‎: PubMed 19954486

DOI‎: 10.1111/j.1537-2995.2008.01987.x

https://www.ncbi.nlm.nih.gov/pubmed/19954486 (abre nova janela)

The early use of fibrinogen, prothrombin complex concentrate, and recombinant-activated factor VIIa in massive bleeding. (abre nova janela)

Fries D

Fonte‎: Transfusion 2013;53 Suppl 1:91S-5S.

Indexado‎: PubMed 23301979

DOI‎: 10.1111/trf.12041

https://www.ncbi.nlm.nih.gov/pubmed/23301979 (abre nova janela)

A Jehovah's Witness with complex abdominal trauma and coagulopathy: use of factor VII and a review of the literature. (abre nova janela)

Haan J, Scalea T

Fonte‎: Am Surg 2005;71(5):414-5.

Indexado‎: PubMed 15986972

https://www.ncbi.nlm.nih.gov/pubmed/15986972 (abre nova janela)

Results of the control trial: efficacy and safety of recombinant activated factor VII in the management of refractory traumatic hemorrhage. (abre nova janela)

Hauser CJ, Boffard K, Dutton R, Bernard GR, Croce MA, Holcomb JB, Leppaniemi A, Parr M, Vincent JL, Tortella BJ, Dimsits J, Bouillon B; CONTROL Study Group.

Fonte‎: J Trauma 2010;69(3):489-500.

Indexado‎: PubMed 20838118

DOI‎: 10.1097/TA.0b013e3181edf36e

https://www.ncbi.nlm.nih.gov/pubmed/20838118 (abre nova janela)

Use of recombinant activated factor VII in patients without hemophilia: a meta-analysis of randomized control trials. (abre nova janela)

Hsia CC, Chin-Yee IH, McAlister VC.

Fonte‎: Ann Surg 2008;248(1):61-8.

Indexado‎: PubMed 18580208

DOI‎: 10.1097/SLA.0b013e318176c4ec

https://www.ncbi.nlm.nih.gov/pubmed/18580208 (abre nova janela)

Rescue treatment with recombinant factor VIIa is effective in patients with life-threatening bleedings secondary to major wound excision: a report of four cases. (abre nova janela)

Johansson PI, Eriksen K, Alsbjørn B

Fonte‎: J Trauma 2006;61(4):1016-8.

Indexado‎: PubMed 17033583

DOI‎: 10.1097/01.ta.0000239261.48022.f1

https://www.ncbi.nlm.nih.gov/pubmed/17033583 (abre nova janela)

Use of recombinant activated factor VII in Jehovah's Witness patients with critical bleeding. (abre nova janela)

Kandane-Rathnayake RK, Isbister JP, Zatta AJ, Aoki NJ, Cameron P, Phillips LE; Australian and New Zealand Haemostasis Registry Steering Committee

Fonte‎: ANZ J Surg 2013;83(3):155-60.

Indexado‎: PubMed 23035873

DOI‎: 10.1111/j.1445-2197.2012.06285.x

https://www.ncbi.nlm.nih.gov/pubmed/23035873 (abre nova janela)

Recombinant factor VIIa in trauma patients with the 'triad of death.' (abre nova janela)

Mitra B, Cameron PA, Parr MJ, Phillips L.

Fonte‎: Injury 2012;43(9):1409-14.

Indexado‎: PubMed 21345431

DOI‎: 10.1016/j.injury.2011.01.033

https://www.ncbi.nlm.nih.gov/pubmed/21345431 (abre nova janela)

Low-dose recombinant factor VIIa for trauma patients with coagulopathy. (abre nova janela)

Stein DM, Dutton RP, Hess JR, Scalea TM.

Fonte‎: Injury 2008;39(9):1054-61.

Indexado‎: PubMed 18656871

DOI‎: 10.1016/j.injury.2008.03.032

https://www.ncbi.nlm.nih.gov/pubmed/18656871 (abre nova janela)

Treatment of excessive bleeding in Jehovah's Witness patients after cardiac surgery with recombinant factor VIIa (Novoseven®). (abre nova janela)

Tanaka KA, Waly AA, Cooper WA, Levy JH.

Fonte‎: Anesthesiology 2003;98(6):1513-5.

Indexado‎: PubMed 12766668

https://www.ncbi.nlm.nih.gov/pubmed/12766668 (abre nova janela)

Alternatives to allogeneic platelet transfusion. (abre nova janela)

Desborough MJ, Smethurst PA, Estcourt LJ, Stanworth SJ.

Fonte‎: Br J Haematol 2016;175(3):381-92.

Indexado‎: PubMed 27650431

DOI‎: 10.1111/bjh.14338

https://www.ncbi.nlm.nih.gov/pubmed/27650431 (abre nova janela)

The early use of fibrinogen, prothrombin complex concentrate, and recombinant-activated factor VIIa in massive bleeding. (abre nova janela)

Fries D

Fonte‎: Transfusion 2013;53 Suppl 1:91S-5S.

Indexado‎: PubMed 23301979

DOI‎: 10.1111/trf.12041

https://www.ncbi.nlm.nih.gov/pubmed/23301979 (abre nova janela)

Plasma fibrinogen level on admission to the intensive care unit is a powerful predictor of postoperative bleeding after cardiac surgery with cardiopulmonary bypass. (abre nova janela)

Kindo M, Hoang Minh T, Gerelli S, Perrier S, Meyer N, Schaeffer M, Bentz J, Announe T, Mommerot A, Collange O, Pottecher J, Cristinar M, Thiranos JC, Gros H, Mertes PM, Billaud P, Mazzucotelli JP

Fonte‎: Thromb Res 2014;134(2):360-8.

Indexado‎: PubMed 24857189

DOI‎: 10.1016/j.thromres.2014.05.008

https://www.ncbi.nlm.nih.gov/pubmed/24857189 (abre nova janela)

Combination of recombinant factor VIIa and fibrinogen corrects clot formation in primary immune thrombocytopenia at very low platelet counts. (abre nova janela)

Larsen OH, Stentoft J, Radia D, Ingerslev J, Sørensen B

Fonte‎: Br J Haematol 2013;160(2):228-36.

Indexado‎: PubMed 23151086

DOI‎: 10.1111/bjh.12118

https://www.ncbi.nlm.nih.gov/pubmed/23151086 (abre nova janela)

Strategies to reduce the use of blood products: a European perspective. (abre nova janela)

Theusinger OM, Felix C, Spahn DR.

Fonte‎: Curr Opin Anaesthesiol 2012;25(1):59-65.

Indexado‎: PubMed 22113184

DOI‎: 10.1097/ACO.0b013e32834dec98

https://www.ncbi.nlm.nih.gov/pubmed/22113184 (abre nova janela)

Desmopressin reduces transfusion needs after surgery: a meta-analysis of randomized clinical trials. (abre nova janela)

Crescenzi G, Landoni G, Biondi-Zoccai G, Pappalardo F, Nuzzi M, Bignami E, Fochi O, Maj G, Calabrò MG, Ranucci M, Zangrillo A

Fonte‎: Anesthesiology 2008;109(6):1063-76.

Indexado‎: PubMed 19034103

DOI‎: 10.1097/ALN.0b013e31818db18b

https://www.ncbi.nlm.nih.gov/pubmed/19034103 (abre nova janela)

Alternatives to allogeneic platelet transfusion. (abre nova janela)

Desborough MJ, Smethurst PA, Estcourt LJ, Stanworth SJ.

Fonte‎: Br J Haematol 2016;175(3):381-92.

Indexado‎: PubMed 27650431

DOI‎: 10.1111/bjh.14338

https://www.ncbi.nlm.nih.gov/pubmed/27650431 (abre nova janela)

Desmopressin in treatment of haematological disorders and in prevention of surgical bleeding. (abre nova janela)

Svensson PJ, Bergqvist PB, Juul KV, Berntorp E

Fonte‎: Blood Rev 2014;28(3):95-102.

Indexado‎: PubMed 24703870

DOI‎: 10.1016/j.blre.2014.03.001

https://www.ncbi.nlm.nih.gov/pubmed/24703870 (abre nova janela)

Coagulopathy caused by vitamin K deficiency in critically ill, hospitalized patients. (abre nova janela)

Alperin JB

Fonte‎: JAMA 1987;258(14):1916-9.

Indexado‎: PubMed 3656602

DOI‎: 10.1001/jama.1987.03400140078028

https://www.ncbi.nlm.nih.gov/pubmed/3656602 (abre nova janela)

Vitamin K deficiency and D-dimer levels in the intensive care unit: a prospective cohort study. (abre nova janela)

Crowther MA, McDonald E, Johnston M, Cook D

Fonte‎: Blood Coagul Fibrinolysis 2002;13(1):49-52.

Indexado‎: PubMed 11994567

DOI‎: 10.1097/00001721-200201000-00007

https://www.ncbi.nlm.nih.gov/pubmed/11994567 (abre nova janela)

The use of fibrin sealant in burn operations. (abre nova janela)

Foster K

Fonte‎: Surgery 2007;142(4 Suppl):S50-4.

Indexado‎: PubMed 18019939

DOI‎: 10.1016/j.surg.2007.06.026

https://www.ncbi.nlm.nih.gov/pubmed/18019939 (abre nova janela)

Use of fibrin sealant in thermal injury. (abre nova janela)

McGill V, Kowal-Vern A, Lee M, Greenhalgh D, Gomperts E, Bray G, Gamelli R

Fonte‎: J Burn Care Rehabil 1997;18(5):429-34.

Indexado‎: PubMed 9313125

DOI‎: 10.1097/00004630-199709000-00011

https://www.ncbi.nlm.nih.gov/pubmed/9313125 (abre nova janela)

Perioperative treatment algorithm for bleeding burn patients reduces allogeneic blood product requirements. (abre nova janela)

Schaden E, Kimberger O, Kraincuk P, Baron DM, Metnitz PG, Kozek-Langenecker S

Fonte‎: Br J Anaesth 2012;109(3):376-81.

Indexado‎: PubMed 22719014

DOI‎: 10.1093/bja/aes186

https://www.ncbi.nlm.nih.gov/pubmed/22719014 (abre nova janela)

Transfusion in trauma: why and how should we change our current practice? (abre nova janela)

Theusinger OM, Spahn DR, Ganter MT.

Fonte‎: Curr Opin Anaesthesiol 2009;22(2):305-12.

Indexado‎: PubMed 19390257

DOI‎: 10.1097/ACO.0b013e3283212c7c

https://www.ncbi.nlm.nih.gov/pubmed/19390257 (abre nova janela)

Viscoelastic point-of-care testing to assist with the diagnosis, management and monitoring of haemostasis: a systematic review and cost-effectiveness analysis. (abre nova janela)

Whiting P, Al M, Westwood M, Ramos IC, Ryder S, Armstrong N, Misso K, Ross J, Severens J, Kleijnen J

Fonte‎: Health Technol Assess 2015;19(58):1-228.

Indexado‎: PubMed 26215747

DOI‎: 10.3310/hta19580

https://www.ncbi.nlm.nih.gov/pubmed/26215747 (abre nova janela)